Genprex, Inc. Company Profile
Background
Genprex, Inc. is a clinical-stage gene therapy company established in 2009 and headquartered in Austin, Texas. The company is dedicated to developing innovative therapies for patients with cancer and diabetes, focusing on administering disease-fighting genes to address unmet medical needs in these patient populations.
Key Strategic Focus
Genprex's strategic focus centers on leveraging its proprietary gene therapy technologies to create novel treatments for cancer and diabetes. The company's oncology program utilizes the Oncoprex® Delivery System, a systemic, non-viral platform that encapsulates gene-expressing plasmids using lipid-based nanoparticles. This system is designed to deliver tumor suppressor genes directly to cancer cells, aiming to restore deficient tumor suppressor proteins. The lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in multiple clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In the diabetes domain, Genprex is developing GPX-002, a gene therapy approach that employs an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas, with the goal of rejuvenating insulin-producing beta cells.
Financials and Funding
As of the latest available data, Genprex's stock is trading at $1.96 per share, reflecting a market capitalization of approximately $8.31 million. The company has engaged in various funding activities to support its research and development initiatives. In 2023, Genprex sold 13,278,666 shares of its common stock under an at-the-market (ATM) facility, generating net proceeds totaling $6,028,104. Additionally, in February 2025, Genprex formed a wholly-owned subsidiary, Convergen Biotech, Inc., to focus on the development and commercialization of its diabetes gene therapy program separately from its oncology initiatives.
Pipeline Development
Genprex's pipeline includes:
- Oncology Program: The lead candidate, Reqorsa® Gene Therapy, is undergoing evaluation in multiple clinical trials for NSCLC and SCLC. The NSCLC program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), and the SCLC program has been granted Orphan Drug Designation.
- Diabetes Program: GPX-002 is in preclinical development for both Type 1 and Type 2 diabetes. The therapy aims to deliver Pdx1 and MafA genes to the pancreas to rejuvenate insulin-producing beta cells.
Technological Platform and Innovation
Genprex's proprietary Oncoprex® Delivery System is a non-viral gene therapy platform that utilizes lipid-based nanoparticles to deliver gene-expressing plasmids directly to target cells. This system is designed to restore deficient tumor suppressor proteins in cancer cells. In the diabetes program, the company employs an AAV vector to deliver Pdx1 and MafA genes to the pancreas, aiming to rejuvenate insulin-producing beta cells.
Leadership Team
- Rodney Varner, JD: Chairman, President, and Chief Executive Officer. Co-founder of Genprex, he has over 35 years of legal experience, including roles in company formation, mergers and acquisitions, and capital raising.
- Dr. Mark S. Berger, MD: Chief Medical Officer. Dr. Berger joined Genprex in September 2021, bringing extensive experience in clinical trial management and oncology.
- David M. Schloss: Senior Vice President of Human Resources. Mr. Schloss oversees human resources strategies and operations at Genprex.
- Thomas C. Gallagher, Esq.: Senior Vice President of Intellectual Property and Licensing. Mr. Gallagher manages the company's intellectual property portfolio and licensing agreements.
- Dr. Suzanne Thornton-Jones, Ph.D.: Senior Vice President of Regulatory Affairs and Quality. Dr. Thornton-Jones is responsible for regulatory affairs and quality assurance at Genprex.
- Celina Laney: Chief of Staff. Ms. Laney supports the executive team in strategic initiatives and operations.
- Dr. Jack A. Roth, F.A.C.S., M.D.: Chairman of the Scientific and Medical Advisory Board. Dr. Roth provides guidance on scientific and medical aspects of Genprex's programs.
Competitor Profile
- Market Insights and Dynamics: The global lung cancer therapeutics market was valued at approximately $20.2 billion in 2024 and is projected to reach $53.9 billion by 2034. The diabetes market is also substantial, with spending related to Type 1 diabetes in the U.S. expected to reach $20.3 billion by 2029, and Type 2 diabetes market sales projected to climb to $57 billion by the same year.
- Competitor Analysis: Genprex faces competition from several biotechnology companies, including Qu Biologics, NexImmune, and Nektar Therapeutics. These companies are also developing gene therapies and immunotherapies for cancer and diabetes, contributing to a competitive landscape in the biotechnology industry.
Strategic Collaborations and Partnerships
Genprex has established research agreements with institutions such as The University of Michigan Rogel Cancer Center and has a lung cancer study collaboration with ALK Positive. These partnerships aim to advance the development of Genprex's gene therapy programs.
Operational Insights
Genprex operates in a highly competitive environment, facing challenges from larger pharmaceutical companies with established oncology drugs. The company must navigate the complexities of clinical development, regulatory approvals, and market penetration to establish its gene therapies as viable treatment options.
Strategic Opportunities and Future Directions
Genprex's strategic roadmap includes advancing its oncology and diabetes gene therapy programs through clinical trials, seeking additional regulatory designations, and expanding its intellectual property portfolio. The formation of Convergen Biotech, Inc. as a wholly-owned subsidiary allows the company to focus on the development and commercialization of its diabetes gene therapy program separately from its oncology initiatives.
Social Media and Website Presence
- Website: www.genprex.com
- Social Media: Twitter, Facebook, LinkedIn
Stock Market Information for Genprex Inc (GNPX)
- Genprex Inc is an equity in the USA market.
- The price is $1.96 currently with a change of -$0.27 (-0.12%) from the previous close.
- The latest open price was $2.15 and the intraday volume is 454,674.
- The intraday high is $2.22 and the intraday low is $1.90.
- The latest trade time is Thursday, February 5, 17:15:00 PST.
